Reviva Pharmaceuticals (NASDAQ:RVPH) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a report released on Monday, Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q1 2024 earnings at ($0.28) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.04) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($1.09) EPS.

Separately, Benchmark reiterated a speculative buy rating and set a $17.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, April 16th.

Reviva Pharmaceuticals Trading Down 1.3 %

Shares of Reviva Pharmaceuticals stock opened at $3.02 on Monday. The firm has a fifty day simple moving average of $3.57 and a 200-day simple moving average of $4.10. Reviva Pharmaceuticals has a 1-year low of $2.67 and a 1-year high of $9.25. The stock has a market capitalization of $84.32 million, a price-to-earnings ratio of -1.84 and a beta of -0.02.

Institutional Trading of Reviva Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. bought a new position in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $72,000. EMC Capital Management boosted its position in Reviva Pharmaceuticals by 1,294.3% during the third quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after purchasing an additional 115,028 shares during the period. Finally, Armistice Capital LLC boosted its position in Reviva Pharmaceuticals by 194.0% during the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after purchasing an additional 1,164,000 shares during the period. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.